clinical failure and its management
DESCRIPTION
Clinical failure and its management. David W. Denning Director, National Aspergillosis Centre University Hospital South Manchester [Wythenshawe Hospital] The University of Manchester. Problems with antifungal therapy. Drug toxicity Drug interactions and low blood levels. Drug toxicities - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/1.jpg)
Clinical failure and its management
David W. DenningDirector, National Aspergillosis CentreUniversity Hospital South Manchester
[Wythenshawe Hospital]The University of Manchester
![Page 2: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/2.jpg)
Problems with antifungal therapy
1. Drug toxicity
2. Drug interactions and low blood levels
![Page 3: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/3.jpg)
ItraconazoleNauseaAnkle swellingPeripheral neuropathyFatigue
VoriconazoleFeeling illConfusion/hallucinations/poor concentrationPhotosensitivity
Drug toxicitiesCommon reasons for stopping therapies
![Page 4: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/4.jpg)
Itraconazole concentrations
in phase 2 studies
Denning et al, Am J Med 1994;97:135
![Page 5: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/5.jpg)
Itraconazole concentrations in relation to timing of samples
Tucker et al, J Am Acad Dermatol 1990;23:593-601
![Page 6: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/6.jpg)
Optimising itraconazole levels – aim between 5 and 17 mg/L
Lestner et al, Clin Infect Dis 2009; 49:928
![Page 7: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/7.jpg)
Itraconazole for ABPA in CF
Sermet-Gaudelus, Antimicrob Ag Chemother 2001;45:1937.
Itraconazole often poorly absorbed and variable penetration
into CF sputum
![Page 8: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/8.jpg)
Generic itraconazole (Sandoz)
Pasqualotto, Int J Antimicrob Ag 2007; 30:93
![Page 9: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/9.jpg)
Approval of itraconazole by the FDA and Europe in 1991
![Page 10: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/10.jpg)
Voriconazole - metabolism
98% metabolised by liverPrimarily metabolised by CYP2C19 and CYP3A4,
less by CYP2C9.
Cirrhosis / prior alcohol abuse and elderly likely predictors of slow metabolisers. Also genetic polymorphism of CYP2C19.
Low levels likely in children, oral therapy and unpredictable.
Usual dosing 150 – 300mg twice daily
Voriconazole datasheet
![Page 11: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/11.jpg)
Random voriconazole concentrations in adults receiving 3mg/Kg BID
1
10
100
1000
10,000
100,000
0 70 140 210 280
days after first dose
Log 1
0 [
Conce
ntr
ati
on (
µg/L
)]
Data from Denning et al, Clin Infect Dis 2002;34:563
Possible toxicity
Very small children may metabolise voriconazole very fast and need dose escalation to ?7-
10mg/Kg BID or 200mg BID
![Page 12: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/12.jpg)
Voriconazole levels in children
Pasqualotto et al, Arch Dis Child 2008;93:578
![Page 13: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/13.jpg)
Cytochrome P450 interactionsFluc Itra Posa Vori
Inhibitor
2C19 + +++ 2C9 ++ + ++ 3A4 ++ +++ +++ ++Substrate
2C19 +++ 2C9 + 3A4 +++ +
Dodds Ashley & Alexander. Drugs Today 2006;41:393.
![Page 14: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/14.jpg)
New section on drug interactions which you can search very quickly
![Page 15: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/15.jpg)
Problems with antifungal therapy
1. Drug toxicity
2. Drug interactions and low blood levels
3. Azole resistance, intrinsic and acquired
![Page 16: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/16.jpg)
32 yr old from Malawi, on HAART Rx- haemoptysis- Aspergillus precipitin titre 1/16
CT scan shows 2 large cavities with aspergillomas, with additional lesions (October 2005)
Chronic cavitary pulmonary aspergillosis (CCPA) in HIV February 2005
Surgical removal would require a pneumonectomySo treated with itraconazole
![Page 17: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/17.jpg)
On HAART Rx, with low viral load, CD4 count >200- New haemoptysis- Aspergillus precipitin titre 1/32
CXR & CT scan showed expansion of inferior cavity
CCPA in HIV February 2007
February 2007 April 2007
MICs A. fumigatus Feb 2007Itraconazole = >8.0mg/mLVoriconazole = 0.5 mg/mLPosaconazole = 1.0 mg/mL
![Page 18: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/18.jpg)
Itraconazole concentrationsNov 05 2.5 mg/LDec 05 3.4 mg/LMarch 06 4.5 mg/LJuly 06 6.7 mg/LFeb 07 8.4 mg/L
CCPA in HIV - low itraconazole concentrations
Do low concentrations of antifungal predispose to the development of
resistance?
![Page 19: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/19.jpg)
microtitre,
RPMI 2% glucose
35°C 48 hrs
2x106/mL
Test inoculum
AF72 AF91
Denning et al, JAC 1997;40:401
![Page 20: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/20.jpg)
confirmation in vivo
Denning et al, JAC 1997;40:401
Strain 5 (AF 72)G54 CYP51A mutation
Strain 6 (AF 91)M220 CYP51A mutation
controls
Itra 25mg/Kg
Itra 75mg/Kg
AmB 5mg/Kg
Itra 75mg/Kg
AmB 5mg/Kg
![Page 21: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/21.jpg)
Development of international standards for susceptibility testing and
breakpoints
![Page 22: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/22.jpg)
Manchester azole MIC distributions
0
50
100
150
200
250
?0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 >8
Numb
er of
isolat
es
Itraconazole MIC (mg/L)
0
50
100
150
200
250
?0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 >8
MIC mg/L
Numb
er of
isolat
es
Voriconazole MIC (mg/L)
0
10
20
30
40
50
?0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 >8
Numb
er of
isolat
es
Posaconazole MIC (mg/L)
modified EUCAST method - 0.5 x 105 not 1-2.5 x 105 cfu/mL
![Page 23: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/23.jpg)
Azole resistance in A. fumigatus in Manchester 1997-2009
Bueid, J Antimicrob Chemother 2010;65:2116. Howard et al, EID 2009; 15:1068
0
10
20
30
40
50
60
70
80
90
100
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
Num
ber
of
pat
ien
t ca
ses
Multi-azole resistant
Itraconazole & posaconazole resistant
Voriconazole resistant
Itraconazole resistant
Fully susceptible
0% 0%7%
3%
0%5%
5%
5%
7%
17%
0%
14%
20%
![Page 24: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/24.jpg)
Clinical features of patients with azole resistant A. fumigatus
17 patients, 15 from UK, different cities
9 had CCPA, all with aspergilloma3 had sputum isolate, with no treatment data2 had ABPA2 had IA1 had Aspergillus bronchitis
13 of 14 patients had prior azole exposure
8 failed therapy and 5 failed to improve (12 itraconazole, 1 voriconazole)
Howard et al, EID 2009; 15:1068
![Page 25: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/25.jpg)
http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop57.pdf
![Page 26: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/26.jpg)
Molecular detection of Aspergillus spp.
in sputum
Denning et al. Clin Infect Dis 2011;
Laboratory result ABPA CPA Normals
Culture positive for A. fumigatus
0/197/42
(16.7%)0/11
qPCR positive for Aspergillus spp
15/19 (78.9%)
30/42 (71.4%)
4/11 (36.4%)
![Page 27: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/27.jpg)
CF and Aspergillus cultures
Baxter, unpublished
Pre-sonication
Post-sonication
![Page 28: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/28.jpg)
Routine culture cfu versus qPCR for AspergillusSputum and BAL
Kirwan, AAA 2012 Abstract
Sample BL AC PC VC JO
culture qPCR culture qPCR culture qPCR culture qPCR culture qPCR
Sputum before 8 32.8 1 32.8 2 33.6 0 34.8
Ist trap 33 28.9 0 37.8 2 36.9 0 33.4
Ist wash (5-20mL) 0 38 0 30.3 0 33.5 2 33.5
BAL (10-70 mL) 0 37.2 0 32.8 0 33.1
LLL BAL 12 34
LLL trap 1 32.7
RML BAL 0 neg
RUL BAL 10mL 0 33.4
RLL (120mL) 0 31.2
Sputum after 3 32.2 0 29.6 0 34.9 1 34.6 0 31.4
E. dermatiditis
![Page 29: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/29.jpg)
Direct detection of resistance mutations in clinical specimens,
without positive cultures
Laboratory result ABPA CPA Normals
Culture positive for A. fumigatus
0/197/42
(16.7%)0/11
qPCR positive for Aspergillus spp
15/19 (78.9%)
30/42 (71.4%)
4/11 (36.4%)
A. fumigatus CYP51A mutation detected directly from qPCR positive sample 6/8 (75%)12/24 (50%) NT
Denning, Clin Infect Dis 2011;52:1123
![Page 30: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/30.jpg)
Problems with antifungal therapy
1. Drug toxicity
2. Drug interactions and low blood levels
3. Azole resistance, intrinsic and acquired
4. Antifungal failure (without resistance/low azole blood levels etc)
5. Immune reconstitution or other ‘switching’ of immune response
![Page 31: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/31.jpg)
Aspergillomas in CF
Turcios – www.aspergillus.ac.uk
![Page 32: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/32.jpg)
Felton, Clin Infect Dis 2010; 51:1383.
![Page 33: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/33.jpg)
Chishimba et al, J Asthma . In press
Second and third line antifungal therapy for ABPA and/or asthma
• 26 patients, ABPA (n = 21) or SAFS (n = 5).• All patients had failed itraconazole (n=14) or developed adverse events (n=12)
![Page 34: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/34.jpg)
Chishimba et al, J Asthma . In press
Second and third line antifungal therapy for ABPA and/or asthma
• 26 patients, ABPA (n = 21) or SAFS (n = 5).• All patients had failed itraconazole (n=14) or developed adverse events
(AEs) (n=12)• 34 courses of therapy, 25 with voriconazole and 9 with posaconazole.
• Voriconazole responses: 17/25 (68%) at 3 months, 15/20 (75%) at 6 months and 12/16 (75%) at 12 months, • Posaconazole responses: 7/9 (78%) at 3, 6 and 12 months for posaconazole. • 18/24 (75%) discontinued oral corticosteroids, 12 of them within 3 months of starting antifungal therapy. • 6/23 (26%) patients on voriconazole had AEs requiring discontinuation before 6 months compared to none on posaconazole (p=0.15). • 4 relapsed (57%), 1 at 3 months and 3 at 12 months after discontinuation.
![Page 35: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/35.jpg)
Inhaled amphotericin B
![Page 36: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/36.jpg)
Dose and reconstitution
• Dose can be increased in 5mg/1ml stages up to 20mg/4mls twice a day or a maximum daily treatment dosage of 1mg/kg
• Reconstitution:– 10ml water for injection added
to 50mg yellow powder (5mg per ml)
– (2ml therefore yields 10mg dose)
– Consider residual volume of nebuliser!
![Page 37: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/37.jpg)
Compressors• Need servicing regularly!• To drive most nebulisers an output of at
least 8 L/m is required
![Page 38: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/38.jpg)
The Pari LC plus with exhaust filter
Nebuliser chamber
Features:
• Fill volume 2ml-8ml• Delivers approx 65% respirable dose• Can go through the dishwasher• Can survive boiling in water
![Page 39: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/39.jpg)
![Page 40: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/40.jpg)
Comparison of Pari LC versus other nebulisers
![Page 41: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/41.jpg)
Another challenge – immune reconstitution
![Page 42: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/42.jpg)
Miceli, Cancer 2007;110:112; Caillot Eur J Radiol 2010;74:e172
Day 0
Day 7
![Page 43: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/43.jpg)
Immune reconstitution in invasive pulmonary aspergillosis, in AIDS
Patient HB Day +14, CD4 cells 84/uL
Sambatakou, Eur J Clin Microbiol Infect Dis 2005;24:628
Patient HB Day +42, after AmB and ITZ
![Page 44: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/44.jpg)
Immune reconstitution in invasive pulmonary aspergillosis, in AIDS
Patient HB Day +64, CD4 cells 340/uL, on
VRCSambatakou, Eur J Clin Microbiol Infect Dis 2005;24:628
Patient HB Day +87, day of death
![Page 45: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/45.jpg)
Several patients have increasing breathlessness with antifungal
therapy
Documented fall in DLCO in one patient
Deaths in others.Mechanism unclear.
Likely benefit from steroids, needs good antifungal cover.
![Page 46: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/46.jpg)
Interferon gamma replacement
Both patients improved with γIFN
Kelleher, Eur Resp J 2006;27:1307
![Page 47: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/47.jpg)
CPA treatment – IFN gamma?
Denning DW et al, Clin Infect Dis 2003; 37(Suppl 3):S265-80.
![Page 48: Clinical failure and its management](https://reader035.vdocument.in/reader035/viewer/2022062718/56812db8550346895d92ecf3/html5/thumbnails/48.jpg)
Management approach
1. Exclude low blood levels – be careful of large dose increases with voriconazole
2. Fungal cultures – test for resistance
3. Exclude or treat bacterial co-infection
4. Use IV therapy if patient very ill
5. Consider surgical resection, gamma IFN, inhaled AmB (if ABPA/SAFS),
6. Long term IV therapy for CPA feasible and partially effective.